Experimental Therapeutics Clinical Trials

Protocol No.PITitle
CALGB-20802Leslie AndritsosEmbedded Protocol to CALGB-100701
AMC-075Robert BaiocchiA Sequential Phase I/Randomized Phase II Trial of Vorinostat and Risk-Adapted Chemotherapy with Rituximab in HIV-Related B-cell Non-Hodgkin's Lymphoma
OSU-13158Tony Bekaii-SaabA Phase Ib/II Clinical Study of BBI608 Administered with Paclitaxel in Adult Patients with Advanced Malignancies
OSU-14005Tony Bekaii-SaabA Phase 3, Multicenter, Open-label, Randomized Study of nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Subjects With Surgically Resected Pancreatic Adenocarcinoma
OSU-13081Tony Bekaii-SaabRandomized, Open Label, Phase 2 Study of MM-111 and Paclitaxel with or without Trastuzumab in Patients with Traditional and Non-Traditional HER2 Expressing Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach Who Have Failed Front Line Metastatic or Locally Advanced Therapy
OSU-13097Tony Bekaii-SaabA Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of AMG 337 in Adult Subjects with Advanced Solid Tumors
OSU-13098Tony Bekaii-SaabA Phase III Study of Chemotherapy With or Without Algenpantucel-L (HyperAcute®-Pancreas) Immunotherapy in Subjects with Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
CALGB-80802Tony Bekaii-SaabA Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib Alone In Patients with Advanced Hepatocellular Carcinoma (HCC).
CALGB-580901Tony Bekaii-SaabEmbedded Companion to CALGB 80802
CALGB-150902Tony Bekaii-SaabEmbedded Companion to CALGB 80802
CALGB-60901Tony Bekaii-SaabEmbedded Companion Study to CALGB 80802
CALGB-70502Tony Bekaii-SaabEmbedded Companion Study to CALGB 80405
CALGB-150506Tony Bekaii-SaabEmbedded Companion Study to CALGB 80405
CALGB-60501Tony Bekaii-SaabEmbedded Companion to CALGB 80405
OSU-08078Tony Bekaii-SaabA prospective, multicenter, randomized, open-label, active-controlled, 2-parallel group, phase III study to compare efficacy and safety of masitinib at 7.5 mg/kg/day to imatinib at 400 or 600 mg in treatment of patients with gastro-intestinal stromal tumor in first line medical treatment
CALGB-80803Tony Bekaii-SaabRANDOMIZED PHASE II TRIAL OF PET SCAN-DIRECTED COMBINED MODALITY THERAPY IN ESOPHAGEAL CANCER
OSU-11147Tony Bekaii-SaabA Multi-Center, Randomized, Placebo-Controlled Phase II Study of Regorafenib in Combination With FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) Versus Placebo With FOLFIRI as Second-Line Therapy in Patients with Metastatic Colorectal Cancer
OSU-11167Tony Bekaii-SaabTwo-Part, Open-Label, Multi-Center Phase 1 Study of Monoclonal Antibody CEP-37250/KHK2804 in Subjects with Advanced Solid Tumors
CALGB-71003Tony Bekaii-SaabEmbedded Companion to CALGB-80803
CALGB-151007Tony Bekaii-SaabEmbedded Companion to CALGB-80803
OSU-13087Erin BertinoAn Open Label, Multicenter, Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-Line Therapy to Patients with Non-Small Cell Lung Cancer
OSU-12117Erin BertinoA Study of HSP90 Inhibitor AT13387 Alone and in Combination with Crizotinib in the Treatment of Non-small Cell Lung Cancer (NSCLC)
OSU-12226Erin BertinoA Phase I Study of BMS-986015, an Anti-KIR Monoclonal Antibody, Administered with Ipilimumab, an Anti-CTLA4 Monoclonal Antibody, in Subjects with Select Advanced Solid Tumors
OSU-13262Erin BertinoMulti-arm, Non-randomized, Open-Label Phase IB Study to Evaluate GSK3052230 in Combination with Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects with Solid Malignancies and Deregulated FGF Pathway Signaling
CALGB-60202Clara BloomfieldEmbedded companion to CALGB 40101: Drug Metabolism and Transport PG in Breast CA patients on CALGB 40101
OSU-11113P. Mark BloomstonA Randomized Prospective Multicenter Trial of Pancreas Resection with and without Routine Intraperitoneal Drainage
CALGB-151005Kristie BlumEmbedded Companion to CALGB-50904
OSU-10049Kristie BlumA Phase 1/II trial of panobinostat and lenalidomide in patients with relasped or refractory Hodgkin's Lymphoma
CALGB-50801Kristie BlumPhase II Trial of Response-Adapted Therapy Based on Positron Emission Tomography (PET) for Bulky Stage I and Stage II Classical Hodgkin Lymphoma
CALGB-150805Kristie BlumEmbedded Companion Study to CALGB-50604
CALGB-150903Kristie BlumEmbedded Companion study to CALGB-50801
CALGB-150913Kristie BlumEmbedded companion to CALGB-50803
CALGB-50904Kristie BlumRANDOMIZED PHASE II TRIAL OF OFATUMUMAB AND BENDAMUSTINE VS. OFATUMUMAB, BORTEZOMIB (NSC #681239, IND #58443) AND BENDAMUSTINE IN PATIENTS WITH UNTREATED FOLLICULAR LYMPHOMA
OSU-11015Kristie BlumA Phase I/II Study of Gemcitabine and Bendamustine in Patients with Relapsed or Refractory Hodgkin's Lymphoma
CALGB-60405Kristie BlumEmbedded companion to CALGB 50303: Pharmacogenomics in CALGB 50303.
CALGB-580603Kristie BlumEmbedded Companion to CALGB-50303: Evaluating the Prognostic Utility of PET Scanning in Lymphoma
OSU-12171Kristie BlumA Phase IIa, Open-Label, Multicenter Study of Single-Agent MOR00208, an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
ECOG-E1411Kristie BlumIntergroup Randomized Phase II Four Arm Study In Patients With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB ¨ R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV¨ R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB ¨ LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV ¨ LR) .
OSU-12106Kristie BlumA Phase II Study of MLN8237 Alone and in Combination with Rituximab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
OSU-13016Kristie BlumA Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma
OSU-13131Kristie BlumA Phase 1 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins, in Patients with Progressive Lymphoma
OSU-13188William BlumA Phase 2 Study of ABT-199 in Subjects with Acute Myelogenous Leukemia (AML)
CALGB-20602William BlumEmbedded companion to CALGB 10503;Correlative science in CALGB 10503
CALGB-20703William BlumEmbedded Companion Study to CALGB-10502
OSU-12006William BlumA Phase I, open, cohort dose escalation trial with BI 836858 in patients with refractory or relapsed acute myeloid leukemia
CALGB-70603John ByrdEmbedded Campanion Study to CALGB-10501
CALGB-20601John ByrdEmbeded Companion Study to CALGB-10501
CALGB-20702John ByrdEmbeded Campion Study to CALGB-10404
OSU-05099John ByrdNormal Spleen and Tonsil Tissue for Research Use.
OSU-05128John ByrdUse of Red Cross Leukopacs as Source of Normal Human Cells for Research Use.
OSU-0017John ByrdChronic Lymphocytic Leukemia Research Consortium Human Subjects Protocol for Sample Collection
OSU-13187John ByrdAn Open-Label, Phase I, Dose-Escalation Study Evaluating the Safety and Tolerability of GDC-0853 in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia
OSU-13225John ByrdA Phase 1, Multicenter, Open-label, and Dose-escalation Study of ACP-196 in Subjects with Chronic Lymphocytic Leukemia
OSU-13018John ByrdA Dose Escalation Study of Ibrutinib with Lenalidomide for Relapsed and Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
OSU-08191Michael CaligiuriImmunologic Studies in Hematological Malignancies: Mechanisms of Action in Natural Killer Cell Targeting of Acute Leukemias
OSU-13204David CarboneIncreasing cures for early stage lung cancer
OSU-11166William CarsonA Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients with Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors
OSU-11117Spero CatalandA Multicenter, Open-label Study to Compare on-Demand Treatment to a Prophylaxis Regimen of Nonacog-alfa (benefix) in Subjects with Moderately Severe to Severe Hemophilia B
OSU-05049Spero CatalandConcurrent Cyclosporine and Plasma Exchange Therapy as Initial Therapy of Thrombotic Thrombocytopenic Purpura (TTP)
OSU-05050Spero CatalandStandardized Therapy of Thrombotic Thrombocytopenic Purpura
OSU-13094Robert CavaliereHSPPC-96 Expanded Access (Compassionate Use) Treatment Protocol for an individual Patient
OSU-13035Bo ChaoA Phase 2 Study of Neratinib and Neratinib Plus Temsirolimus in Patients with Non-Small Cell Lung Cancer Carrying Known HER2 Activating Mutations
OSU-13118Bo ChaoDouble blind, randomised, multicentre, phase II study of nintedanib in combination with pemetrexed / cisplatin followed by continuing nintedanib monotherapy versus placebo in combination with pemetrexed / cisplatin followed by continuing placebo monotherapy for the treatment of patients with unresectable malignant pleural mesothelioma
OSU-13100Bo ChaoA phase III, multicenter, randomized, open-label study of oral LDK378 versus standard chemotherapy in adult patients with ALK-rearranged (ALK-positive) advanced non-small cell lung cancer who have been treated previously with chemotherapy (platinum doublet) and crizotinib
OSU-13230Bo ChaoA Phase II, Multicenter, Single-Arm Study of MPDL3280A in Patients with PD-L1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
OSU-13244Bo ChaoA Phase I Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2879552 Given Orally in Subjects with Relapsed/Refractory Small Cell Lung Carcinoma
OSU-13275Bo ChaoA Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)
OSU-14029Bo ChaoAn Open-Label, Randomized, Phase 3 Trial of Nivolumab versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer
OSU-13190Beth ChristianA Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination with Rituximab,Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
OSU-13004Beth ChristianA Phase I Dose Escalation Study of Immunotherapy with IMMU-114 in Patients with Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
OSU-13022Beth ChristianA Phase I Study of Ibrutinib (PCI-32765) in Combination with Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma
CALGB-150910Beth ChristianEmbedded Companion to CALGB-50901
OSU-13184Kristen CiomborA Phase 1 Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics and Safety of Crizotinib in Advanced Cancer Patients
OSU-13159Kristen CiomborA Phase II Clinical Study of BBI608 in Adult Patients with Advanced Colorectal Cancer
CALGB-150403Steven ClintonEmbedded companion to CALGB 90202: N-telopeptide as a prognostic marker for PCa patients on 90202
OSU-13232David CohnCompassionate Use Protocol:ABT-888 FOR A SINGLE PATIENT WITH RECURRENT,PLATINUM RESISTANT OVARIAN CANCER.THE PATIENT HAS BRCA MUTATION.
OSU-12241David CohnCompassionate Use Protocol : International, multicenter, open-label, treatment-extension study for subjects who completed a Phase 1 or Phase 2 parental study to continue receiving treatment with SAR245408 or SAR245409 as a monotherapy or as a combination regimen
OSU-05041Albert de la ChapelleGenetic Ancestry and its Implications in Cytogenetic and Molecular Abnormalities of Acute Myeloid Leukemia.
CALGB-60402Steve DevineEmbedded companion to CALGB 100103: Busulfan Pharmacokinetics in Elderly Leukemic Patients in CALGB 100103
OSU-0241Steve DevineProtocol for a Research Sample Repository for Allogeneic Hematopoietic Stem Cell Transplantation (A National Marrow Donor Program Protocol).
OSU-0242Steve DevineA Research Database for Hematopoietic Cell Transplantation and Cellular Therapies (A National Marrow Donor Program Protocol).
OSU-11087Steve DevineA multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) for transplantation in pediatric and adult patients with hematologic malignancies and other indications
CALGB-151001Steve DevineEmbedded Companion Study to CALGB-100801
OSU-12213Steve DevineA Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients with Hematological Malignancies
RTOG-1216Virginia DiavolitsisRandomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered with Concurrent Cisplatin Versus Docetaxel Versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of The Head And Neck
RTOG-1008Virginia DiavolitsisA Randomized Phase II Study of Adjuvant Concurrent Radiation and Chemotherapy versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
OSU-11052Yvonne EfeberaA Phase 1, Open-Label, Multicenter, Dose-Escalation Study to Evaluate the Safety and Tolerability of Intravenous Administration of RGI-2001 in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT)
OSU-13248Yvonne EfeberaMichigan Acute Graft-versus-Host Disease International Consortium (MAGIC): A Database and Biorepository
OSU-13168Yvonne EfeberaPhase I Trial of Brentuximab Vedotin for Steroid Refractory Acute Graft-vs.-Host Disease (GVHD)
OSU-13128Yvonne EfeberaPhase I/II Study of Lenalidomide in Combination with Anti-PD-1 monoclonal antibody CT-011 in Patients with Relapsed/Refractory Multiple Myeloma
ALLIANCE-A061202Yvonne EfeberaA PHASE I/II STUDY OF POMALIDOMIDE, DEXAMETHASONE AND IXAZOMIB VS. POMALIDOMIDE AND DEXAMETHASONE FOR PATIENTS WITH MULTIPLE MYELOMA REFRACTORY TO LENALIDOMIDE AND PROTEASOME INHIBITOR-BASED THERAPY
OSU-12105James ElderA Continuation Protocol for Patients Previously Enrolled in a Study of Toca 511
OSU-13044Michael EzziePulmonary Rehabilitation in locally advanced Non-Small Cell Lung Cancer
OSU-13093William FarrarNSABP B-50-I: A Randomized, Multicenter, Open-Label Phase III Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy for Patients with HER2-Positive Primary Breast Cancer who have Residual Tumor Present Pathologically in the Breast or Axillary Lymph Nodes Following Preoperative Therapy
SWOG-S1207William FarrarPhase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer. e3 Breast Cancer Study- evaluating everolimus with endocrine therapy.
NSABP-B-47William FarrarRandomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
NSABP-B-43William FarrarA Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy.
OSU-12062Ramiro GarzonA Phase I Study of the Safety, Pharmacokinetics and Pharmacodynamics of Escalating Doses of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients with Advanced Hematological Malignancies
OSU-13182Ramiro GarzonPhase I Study of Decitabine (Dacogen) and Selinexor (KPT-330) in Acute Myeloid Leukemia
RTOG-3501Maura GillisonTRYHARD: A PHASE II, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY OF LAPATINIB (TYKERB®) FOR NON-HPV LOCALLY ADVANCED HEAD AND NECK CANCER WITH CONCURRENT CHEMORADIATION.
OSU-11124Maura GillisonRandomized Double-Blind Phase II Trial of Everolimus Versus Placebo as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN)
RTOG-0920Maura GillisonA Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
OSU-11182Richard GoldbergA Phase II Study of the Combination of Aflibercept (VEGF-Trap) plus Modified FOLFOX 6 in Patients with Previously Untreated Metastatic Colorectal Cancer
OSU-12033Gayle GordilloMASTECTOMY RECONSTRUCTION OUTCOMES CONSORTIUM (MROC) STUDY
OSU-08111John GreculaMR-Predictive-Assay in Pre-Operative Lung Cancer Therapy: Response/Resectability
CALGB-150712John GreculaEmbedded Companion Study to CALGB 30610
CALGB-70702John GreculaEmbedded Companion to CALGB 30610
CALGB-30610John GreculaPhase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin and Etoposide
OSU-12214Michael GreverA Phase II Study of the BRAF Inhibitor, Vemurafenib, in Patients with Relapsed or Refractory Hairy Cell Leukemia
OSU-13151John HaysRandomized phase II study of intravenous 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine® NSC #663249) cisplatin-radiochemotherapy versus intravenous cisplatin-radiochemotherapy in women diagnosed with stage IB-IVA cervical cancer and stage II-IVA vaginal cancer
OSU-13257John HaysA Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications
OSU-13192Craig HofmeisterA Multicenter, Randomized, Open-label, Phase 2 Study of Carfilzomib with or without ARRY-520 in Patients with Advanced Multiple Myeloma
OSU-07012Craig HofmeisterRetrospective Case-Control Study of the Effect of Statin use on Clinical Response to Autologous Stem Cell Transplantation in Myeloma Patients.
OSU-11048Craig HofmeisterA Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients with Advanced Hematological Malignancies
OSU-11159Craig HofmeisterA PHASE 1, MULTICENTER, OPEN-LABEL, DOSEESCALATION STUDY TO DETERMINE THE MAXIMUM TOLERATED DOSE (MTD) FOR THE COMBINATION OF POMALIDOMIDE, BORTEZOMIB AND LOW-DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
OSU-11163Samantha JaglowskiA Pilot Study of Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients with Relapsed/Refractory Hodgkin Lymphoma
OSU-12162Samantha JaglowskiA Phase I Study of Milatuzumab (hLL1) for Prevention of Acute Graft Versus Host Disease Following Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant in Patients with Hematologic Malignancies
OSU-06061Sonata JodeleExpanded Access Protocol for Purging of Peripheral Blood Stem Cells or Bone Marrow from Patients with High Risk Neuroblastoma Prior to Autologous Transplantation Under FDA Investigational Device Exemption BB-IDE-2259
CALGB-150711Jeffrey JonesEmbedded Campanion Study to CALGB-50701
OSU-12200Jeffrey JonesA Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 (Ibrutinib) for Treatment of Relapsed Hairy Cell Leukemia
OSU-12142Jeffrey JonesA Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
OSU-12101Jeffrey JonesA PHASE Ib MULTICENTER DOSE-FINDING AND SAFETY STUDY OF GDC-0199 AND OBINUTUZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY OR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA
OSU-14051Jeffrey JonesA Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia Subjects with Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy
OSU-14099Jeffrey JonesA Multicenter, Open-label, Phase 1 Pilot Study of ACP-196 in Combination with ACP-319 in Subjects with Relapsed/Refractory Chronic Lymphocytic Leukemia
OSU-13210Kari KendraThe NEMO trial (NRAS melanoma and MEK inhibitor): A randomized Phase III, open label, multicenter, two-arm study comparing the efficacy of MEK162 versus dacarbazine in patients with advanced unresectable or metastatic NRAS mutation-positive melanoma
OSU-12165Kari KendraA phase III randomized double blind study of dabrafenib (GSK2118436) in COMBInation with trametinib (GSK1120212) versus two placebos in the ADjuvant treatment of high-risk BRAF V600 mutation-positive melanoma after surgical resection.
OSU-13124Kari KendraA Phase I expansion cohort evaluating the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in patients with unresectable melanoma
SWOG-S1221Kari KendraPhase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination with the BRAF Inhibitor Dabrafenib in Patients with BRAF Mutant Cancer
OSU-11024Kari KendraBRF114144: A Rollover Study to Provide Continued Treatment with GSK2118436 to Subjects with BRAF Mutation-Positive Tumor
OSU-10036Hooman KhabiriA Humanitarian Device Exemption Treatment Protcol of TheraSphere® For Treatment of Unresectable Hepatocellular Carcinoma
OSU-07068Rebecca KlisovicCorrelative Biomarker Study for MPD-RC Treatment Studies in the Philadelphia Chromosome Negative MPD
OSU-07069Rebecca KlisovicMyeloproliferative Disorder Research Consortium (MPD-RC) Research Tissue Bank
OSU-13111Rebecca KlisovicA phase I study of recombinant L-asparaginase encapsulated in erythrocytes (ERYASP) in combination with the CALGB regimen during induction and consolidation phases for frontline therapy of patients older than 40 years with Philadelphia chromosome-negative acute lymphoblastic leukemia
OSU-13112Rebecca KlisovicMyeloproliferative Disorders-Research Consortium (MPD-RC) MPD-RC Protocol 114 Exploring the Potential of Dual Kinase JAK 1/2 Inhibitor Ruxolitinib (INC424) with Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis
OSU-12163Rebecca KlisovicA Phase IIa, Single-Arm,Open-Label Study of MOR00208,a Humanized Fc-Engineered Anti-CD19 Antibody, in Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL).
OSU-13195Rebecca KlisovicA phase II randomized, multicenter study of treatment-free remission in chronic myeloid leukemia in chronic phase(CML-CP) patients who achieve and sustain MR4.5 after switching to nilotinib
OSU-07042Michael KnoppImaging of the Prostate Gland Using High Field Strength 3T MRI
OSU-0361Michael KnoppDynamic Contrast Enhanced Magnetic Resonance Imaging for Non-Invasive Diagnostic Work-Up in Solid Tumors of the Eye and Orbit.
OSU-08063Michael KnoppImaging of the Bladder Tumor Using Clinical 3 Tesla MRI and Ex-Vivo Ultra-high-field MRI
CALGB-150707Kavitha KosuriEmbedded Substudy "A Phase II Study of Dasatinib (NSC # 732517) in Patient w/ Previously Treated Malignant Mesothelioma"
OSU-0384Eric KrautUniversal Data and Serum Specimen Collection System for Hemophilia
OSU-05021Eric KrautEpidemiology and Treatment of Circulating Anticoagulants in Patients with Hemophilia and VonWillebrand's Disease - The HTRS Registry
OSU-06020Eric KrautAn Evaluation of Qualitative Platelet Disorders in Patients with Inherited Disorders of Coagulation.
OSU-11108Tim LautenschlaegerBiomarker discovery for toxicity and survival in Radiation Oncology: an integrative molecular-clinical approach
OSU-12158Tim LautenschlaegerBiomarker Identification for Bladder Cancer Patients
OSU-05094Sean LawlerInvestigating Novel Therapeutic Strategies for Brain Tumor Treatment.
ALLIANCE-A011106Rachel LaymanALTernate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant TrEatment (ALTERNATE) in postmenopausal women: A Phase III Study
OSU-0025David LucasDrug Sensitivity & Apoptosis Studies in Hematologic Malignancies
SWOG-S1007Maryam LustbergA Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less
OSU-14157Maryam LustbergCompassionate use of ABT 888 for a patient with metastatic breast cancer
OSU-14077Erin MacraeA Phase 1 Dose Escalation Study Evaluating the Safety and Tolerability of PF-06650808 in Patients with Advanced Solid Tumors
OSU-13150Erin MacraeA randomized Phase II study of adjuvant Trastuzumab emtansine (T-DM1) vs. Paclitaxel in combination with Trastuzumab for Stage I HER2-positive Breast Cancer (ATEMPT Trial)
OSU-12067Erin MacraeDecision Impact Analysis of Foundation Medicine's Next Generation Sequencing Test in Advanced Solid Tumor Malignancies
OSU-13117Erin MacraeA Single Arm, Phase II Study of Single Agent Trametinib Followed by Trametinib in Combination with GSK2141795 in Patients with Advanced Triple Negative Breast Cancer
OSU-13027Kami MaddocksA Phase I Study of BKM120 and Rituximab in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma
OSU-12095Kami MaddocksA Phase 1b, Open Label Study to Evaluate the Safety and Efficacy of TRU-016 in Combination with Rituximab in Patients with Chronic Lymphocytic Leukemia
ECOG-E1412Kami MaddocksRandomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma
OSU-11179Kami MaddocksA Phase I, Multi-center, Open-label Study of IMGN529 Administered Intravenously in Adult Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma
CALGB-21101Guido MarcucciEmbedded Companion to CALGB-11002
CALGB-361101Guido MarcucciEmbedded Companion to CALGB-11002
CALGB-361006Guido MarcucciEmbedded Companion to CALGB-11001
CALGB-21003Guido MarcucciEmbedded Companion to CALGB-11001
CALGB-211006Guido MarcucciEmbedded Companion to CALGB-11002
CALGB-60706Guido MarcucciEmbeded Campanion Study to CALGB 10603
RTOG-0534Douglas MartinA Phase III Trial of Short Term Androgen Deprivation with Pelvic Lymph Node or Prostate Bed Only Radiotherapy in Prostate Cancer Patients with a Rising PSA After Radical Prostatectomy
RTOG-1115Douglas MartinPhase III Trial of Dose Escalated Radiation Therapy and Standard Androgen Deprivation Therapy (ADT) with a GnRH Agonist vs. Dose Escalated Radiation Therapy and Enhanced ADT with a GnRH Agonist and TAK-700 for Men with High Risk Prostate Cancer
OSU-08118Ehud MendelFunctional Outcome in Patients Following Surgical Decompression and Stabilization for Spinal Metastases: Surgical Impact and Quality of Life
OSU-11151J. Paul MonkPhase I/II Study of High Dose Interleukin 2, Aldesleukin, in Combination with the Histone Deacetylase Inhibitor Entinostat in Patients with Metastatic Renal Cell Carcinoma
CALGB-90203J. Paul MonkA Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy versus Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer
CALGB-150413J. Paul MonkEmbedded companion to CALGB 90203:
CALGB-150412J. Paul MonkEmbedded companion to CALGB 90203:
ALLIANCE-A031203J. Paul MonkRANDOMIZED PHASE II STUDY COMPARING CABOZANTINIB (NSC #761968 AND IND #116059) WITH COMMERCIALLY SUPPLIED SUNITINIB IN PATIENTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA
SWOG-S1216J. Paul MonkA Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer
ALLIANCE-A031201Amir MortazaviPHASE III TRIAL OF ENZALUTAMIDE (NSC # 766085) VERSUS ENZALUTAMIDE, ABIRATERONE AND PREDNISONE FOR CASTRATION RESISTANT METASTATIC PROSTATE CANCER
CALGB-60701Ewa MrozekEmbedded Companion to CALGB-40601
CALGB-150702Ewa MrozekEmbedded Companion to CALGB-40601
OSU-12094Herbert NewtonA Prospective, Multi-center Trial of NovoT T F-100A Together With Temozolomide Compared to Temozolomide Alone in Patients with Newly Diagnosed GBM
OSU-12079Herbert NewtonAn International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GMCSF with Adjuvant Temozolomide in Patients with Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma
OSU-08028Ryan NiederkohrRetrospective Evaluation of the Accuracy of PET/CT with Respect to Surgiscal Planning in Patients with Colorectal Cancer
OSU-13268Anne NoonanAn International, Multi-Center, Double-Blind, Randomized, Phase III Trial of 90Y-Clivatuzumab Tetraxetan plus Low-Dose Gemcitabine Versus Placebo plus Low-Dose Gemcitabine in Patients with Metastatic (Stage IV) Pancreatic Adenocarcinoma Who Received at Least Two Prior Treatments (PANCRIT-1)
OSU-13214David O'MalleyPhase II Randomized Double Blind Placebo Controlled Trial of Combination of Pimasertib with SAR245409 or of Pimasertib with SAR245409 Placebo in Subjects with Previously Treated Unresectable Low Grade Ovarian Cancer
OSU-13259David O'MalleyA Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients with Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
GOG-0279David O'MalleyA PHASE II TRIAL EVALUATING CISPLATIN (NSC #119875) AND GEMCITABINE (NSC # 613327) CONCURRENT WITH INTENSITY-MODULATED RADIATION THERAPY (IMRT) IN THE TREATMENT OF LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE VULVA
OSU-14058David O'MalleyA Phase III Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients who are in Complete or Partial Response Following Platinum based Chemotherapy
GOG-0278David O'MalleyEvaluation of Physical Function and Quality of Life (QOL) Before and After Non-Radical Surgical Therapy (Extra Fascial Hysterectomy or Cone Biopsy with Pelvic Lymphadenectomy) for STAGE IA1 (LVSI+) and IA2-IB1 (¡Ü 2CM) Cervical Cancer
OSU-13148David O'MalleyA Phase 2, Open-Label Study of Rucaparib in Patients with Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
GOG-3004David O'MalleyA Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients with BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer following First Line Platinum Based Chemotherapy.
OSU-13218David O'MalleyRandomized controlled study comparing AEZS-108 with doxorubicin as second line therapy for locally advanced, recurrent or metastatic endometrial cancer
GOG-0229ODavid O'MalleyA Randomized Phase II Study with a Safety Lead-In to Assess the Antitumor Efficacy of the MEK Inhibitor Trametinib Alone or in Combination with GSK2141795, an AKT Inhibitor, in Patients with Recurrent or Persistent Endometrial Cancer
GOG-0277David O'MalleyA PHASE III RANDOMIZED TRIAL OF GEMCITABINE (NSC# 613327) PLUS DOCETAXEL (NSC# 628503) FOLLOWED BY DOXORUBICIN (NSC# 123127) VERSUS OBSERVATION FOR UTERUS-LIMITED, HIGH-GRADE UTERINE LEIOMYOSARCOMA
GOG-0275David O'MalleyA PHASE III RANDOMIZED TRIAL OF PULSE ACTINOMYCIN-D VERSUS MULTI-DAY METHOTREXATE FOR THE TREATMENT OF LOW-RISK GESTATIONAL TROPHOBLASTIC NEOPLASIA
OSU-13140David O'MalleyA Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer.
OSU-13059David O'MalleyA Phase 1, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMGN853 in Adults with Ovarian Cancer and other FOLR1-Positive Solid Tumors
OSU-13066David O'MalleyThe MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer): A Multinational, Randomized, Open-label Phase 3 Study of MEK162 vs. Physician¿s Choice Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary, Fallopian Tube or Primary Peritoneum
GOG-213David O'MalleyPhase III Randomized Controlled Clinical Trial of Carboplatin & Paclitaxel in Combination w/ Bevacizumab followed by Bevacizumab & Secondary Cytoreductive Surgery in Platinum-sensitive Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer
GOG-9923David O'MalleyA Phase I Study of Carboplatin/Paclitaxel/CTEP-Supplied Agent Bevacizumab [NSC #704865, IND #7921] and CTEP-Supplied Agent ABT-888 [NSC #737664, IND #77840] in Newly Diagnosed Patients with Previously Untreated Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
GOG-0264David O'MalleyA Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary
GOG-0274David O'MalleyA Phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: THE OUTBACK TRIAL
GOG-0076HHDavid O'MalleyA Limited Access Phase I/II Trial of Paclitaxel, Cisplatin and Ctep Supplied Agent Abt-888 (Velaparib) (Ind#77840, Nsc#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
OSU-12038David O'MalleyRandomized Phase II Evaluation of Carboplatinipaclitaxel with and without Trastuzumab (Herceptin®) in Her2/Neu+ Patients with Advancedirecurrent Uterine Serous Papillary Carcinoma
OSU-13120Thomas OlenckiA Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects with Metastatic Renal Cell Carcinoma that has Progressed after Prior VEGFR Tyrosine Kinase Inhibitor Therapy
ALLIANCE-A091201Thomas OlenckiRandomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
OSU-12169Greg OttersonPHASE 1 SAFETY, PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF PF-02341066, A C-MET/HGFR SELECTIVE TYROSINE KINASE INHIBITOR, ADMINISTERED ORALLY TO PATIENTS WITH ADVANCED CANCER
ECOG-E5508Greg OttersonRandomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC
CALGB-150908Greg OttersonEmbedded Protocol to CALGB-30801
CALGB-580702Greg OttersonEmbedded Campanion Study to CALGB 30704
OSU-07061Enver OzerA Pilot Study Assessing Transoral Robotic Surgery (TORS) for Oral and Laryngopharyngeal Benign and Malignant Lesions Using the Da Vinci Robotic Surgical System.
ECOG-E3311Enver OzerPhase II Randomized Trial of Transoral Surgical Resection followed by Low-dose or Standard-dose IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer
OSU-12002Mitch PhelpsA PROSPECTIVE, DOUBLE-BLINDED, OBSERVATIONAL CLINICAL COHORT STUDY OF THE ASSOCIATION BETWEEN TACROLIMUS EXPOSURE AND CYP3A4, CYP3A5 GENOTYPES IN ADULT HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS
SWOG-S1011Kamal PoharA Phase III Surgical Trial to Evaluate the Benefit of a Standard versus an Extended Pelvic Lymphadenectomy Performed at time of Radical Cystectomy for Muscle Invasive Urothelial Cancer
OSU-05075Pierluigi PorcuA Retrospective Analysis of Clinical Presentation and Therapeutic Outcomes in T/NK-cell Lymphomas at the OSUCCC as a Benchmark for Future Translational Studies, Clinical Trial Design and Prediction of Accrual.
OSU-09073Pierluigi PorcuComputer-aided Clinical Image Analysis for Cutaneous Lymphomas
OSU-12197Pierluigi PorcuOpen-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 (mogamulizumab) Versus Vorinostat in Subjects with Previously Treated Cutaneous T-Cell Lymphoma
OSU-12206Pierluigi PorcuA Phase 1 Dose Escalation Study of OMP-52M51 in Subjects with Lymphoid Malignancies
OSU-13015Pierluigi PorcuA randomized, double-blind, placebo-controlled, phase 3 study of CH-P and brentuximab vedotin versus CHOP in the front-line treatment of patients with CD30-positive mature T-cell lymphomas
OSU-10025Stephen PovoskiRestrospective Evaluation of Patients Undergoing Surgery and Same-Day Intravenous Administration of 18F-FDG
ECOG-E2108Stephen PovoskiA Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cancer
OSU-13072Vinay PuduvalliPhase I/II Adaptive Randomized Trial of Bevacizumab versus Bevacizumab plus Vorinostat in Adults with Recurrent Glioblastoma
OSU-13089Vinay PuduvalliAn Open Label Phase 1b/2 Study of Orally Administered PLX3397 in Combination with Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma
OSU-13224Vinay PuduvalliBTTC11-01: Randomized, Double-Blind, Placebo-Controlled Trial of Lacosamide for Seizure Prophylaxis in Patients with High-Grade Gliomas
RTOG-1119Allison QuickPHASE II RANDOMIZED STUDY OF WHOLE BRAIN RADIOTHERAPY IN COMBINATION WITH CONCURRENT LAPATINIB IN PATIENTS WITH BRAIN METASTASIS FROM HER2-POSITIVE BREAST CANCER A COLLABORATIVE STUDY OF RTOG AND KROG
OSU-13153Bhuvaneswari RamaswamyCompassionate Use of ABT-888 for a Patient with Metastatic Breast Cancer
OSU-13237Bhuvaneswari RamaswamyA Randomized Double-Blind, Placebo-Controlled Study of LEE011 in Combination with Letrozole for the Treatment of Postmenopausal Women with Hormone Receptor Positive, HER2-Negative, Advanced Breast Cancer who Received no Prior Therapy for Advanced Disease
PRECOG-PRE0102Bhuvaneswari RamaswamyRandomized, Double-Blind, Placebo-Controlled Phase II Trial of Fulvestrant (Faslodex) plus Everolimus in Post-Menopausal Patients with Hormone-Receptor Positive Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy
CALGB-150804Bhuvaneswari RamaswamyEmbedded companion study to CALGB 70604
CALGB-60803Bhuvaneswari RamaswamyEmbedded companion study to CALGB 70604
OSU-14003Ashley RoskoA Phase 1b / 2 Multicenter, Open Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of ACY-1215 in Combination with Pomalidomide and Low-dose Dexamethasone in Patients with Relapsed-and-Refractory Multiple Myeloma
OSU-12072Patrick RossPhotodynamic Therapy (PDT) Oncology Registry
SLE-05001Brad RovinA Phase III, randomized, double-blind placebo-controlled, multicenter study to evaluate the efficacy and safety of retiximab in subjects with ISN/PRS class III or IV lupus nephritis
ECOG-E1305Panayiotis SavvidesA Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer
OSU-13141Panayiotis SavvidesA Phase I/II clinical trial of sorafenib in combination with cisplatin and docetaxel in patients with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN)
OSU-10119Thomas ScharschmidtEstablishing Sarcoma Xenografts
NCCTG-N1048Carl Schmidt A Phase II/III trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision.
OSU-11084Ahmad ShabsighOpen Vs Robotic-Assisted Radical Cystectomy: A Randomized Trial
RTOG-0912Manisha ShahA Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (Imrt), Paclitaxel and Pazopanib (Nsc 737754)/Placebo,for the Treatment of Anaplastic Thyroid Cancer
OSU-12064Manisha ShahA Randomized Phase 2 Study of Single Agent Dabrafenib (BRAFi) vs. Combination Regimen Dabrafenib (BRAFi) and Trametinib (MEKi) in Patients with BRAF Mutated Thyroid Carcinoma
OSU-12066Manisha ShahA Phase I Trial of GSK2118436 (BRAFi) and Pazopanib in Patients with BRAF-Mutated Advanced Malignant Tumors
ECOG-E2211Manisha ShahA Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients with Advanced Pancreatic Neuroendocrine Tumors
ALLIANCE-A021202Manisha ShahProspective Randomized Phase II Trial of Pazopanib(NSC #737754, IND #75648) versus Placebo in Patients with Progressive Carcinoid Tumors
OSU-13070Manisha ShahPhase 2 Study of Pioglitazone in follicular-patterned thyroid cancers that contain the PAX8-PPARgamma fusion gene
OSU-12154Manisha ShahPhase II Study of Cabozantinib in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Who Progressed on First-Line VEGFR-Targeted Therapy
OSU-12055Alicia TerandoFeasibility and Safety of Minimally Invasive Inguinal Lymph Node Dissection in Patients with Melanoma
OSU-06112Amanda TermuhlenDose Intensive Chemotherapy for Children Less than Ten Years of Age Newly-Diagnosed with Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation with Myeloablative Chemotherapy (Thiotepa and Carboplatin, with or without Etoposide) and Autologous Stem Cell Rescue.
AMC-080Sumithira VasuAllogeneic Hematopoietic Cell Transplant for Hematological Cancers and Myelodysplastic Syndromes in HIV-Infected Individuals
OSU-11066Sumithira VasuKIR Genotyping for Unrelated Donor (URD) Selection Prior to Hematopoietic Cell Transplantation (HCT) for AML: Selecting a Favorable KIR Donor
OSU-12097Sumithira VasuA multicenter safety study of unlicensed investigational cryopreserved cord blood units (CBUs) manufactured by the National Cord Blood Program (NCBP) and provided for unrelated hematopoietic stem cell transplantation of pediatric and adult patients
BMTCTN-1101Sumithira VasuA Multi-Center, Phase III, Randomized Trial of Reduced Intensity (RIC) Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) versus HLA-Haploidentical Related Bone Marrow (Haplo) for Patients with Hematologic Malignancies
OSU-12091Sumithira VasuA PHASE 2, CONTROLLED TRIAL, OF A SINGLE PROHEMA-CB UNIT (EX VIVO MODULATED HUMAN CORD BLOOD CELLS) AS PART OF A DOUBLE UMBILICAL CORD BLOOD TRANSPLANT FOLLOWING MYELOABLATIVE OR REDUCED INTENSITY CONDITIONING FOR PATIENTS AGE 15-65 YEARS WITH HEMATOLOGIC MALIGNANCIES
BMT-CTN1102Sumithira VasuA Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Intermediate-2 and High Risk Myelodysplastic Syndrome
OSU-12167Miguel VillalonaA Phase II study of the BRAF inhibitor dabrafenib as a single agent and in combination with the MEK inhibitor trametinib in subjects with BRAF V600E mutation positive metastatic (stage IV) non-small cell lung cancer
OSU-07082Miguel VillalonaAnalysis of FANCD2 Protein Monoubiquitin Status and Nuclear Foci Formation in the Primary Solid Tumors
OSU-09100Miguel VillalonaABT-888 as monotherapy and in combination with Mitomycin C in patients with solid tumors with deficiency in homologous recombination repair.
OSU-11021Alison WalkerResearch database for undiagnosed cytopenias.
OSU-11186Alison WalkerPhase I Study of the Combination of Bortezomib and Sorafenib followed by Decitabine in Elderly Patients with Acute Myeloid Leukemia
OSU-11130Alison WalkerPhase I Study of AR-42 and Decitabine in Acute Myeloid Leukemia
OSU-11013Katherine WalshA Phase 1, Dose Escalation, Multicenter Study of Two Subcutaneous Regimens of SGI-110, a DNA Hypomethylating Agent, in Subjects with Intermediate-2 or High-Risk Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)
OSU-12234Katherine WalshRandomized Phase II Study of Epigenetic Priming Using Decitabine with Induction Chemotherapy in Patients with Acute Myelogenous Leukemia (AML) (A New York Cancer Consortium Study)
OSU-06045Brian WeissA Compassionate Use Protocol Using I-Metaiodobenzylguandine (131 I-MIBG)Therapy in Patients with Refractory Neuroblastoma.
OSU-12223Meng WelliverA Pilot Study of Pleural Photodynamic Therapy for Patients with Pleural Malignancy
OSU-13211Robert WesolowskiAn Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of VX-970 in Combination With Cytotoxic Chemotherapy in Subjects With Advanced Solid Tumors
OSU-10152Robert WesolowskiPhase 1 Study of IMC-CS4, a Monoclonal Antibody Targeted to the CSF-1 Receptor (CSF-1R), in Subjects With Advanced Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy is Available
CALGB-150709Robert WesolowskiEmbedded Companion to CALGB-40603
CALGB-60703Robert WesolowskiEmbedded Companion to CALGB-40603
RTOG-1304Julia WhiteA Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
RTOG-1112Terence WilliamsRandomized Phase III Study of Sorafenib versus Stereotactic Body Radiation Therapy followed by Sorafenib in Hepatocellular Carcinoma
OSU-13031Jennifer WoyachA Phase II Study of MOR00208 in Combination with Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL)Prolymphocytic Leukemia (PLL) or Patients with Untreated CLL/SLL/PLL
ALLIANCE-A041202Jennifer WoyachA Randomized Phase III Study of Bendamustine Plus Rituximab versus Ibrutinib Plus Rituximab versus Ibrutinib Alone in Untreated Older Patients (¡Ý 65 Years Of Age) with Chronic Lymphocytic Leukemia (CLL)
OSU-13176Chadwick WrightPET/CT-Derived Hepatopulmonary Shunt Fraction Following Yttrium-90 Radioembolization
OSU-11131Christina WuA Phase II Study of Panitumumab in Combination with FOLFIRI after Progression on FOLFIRI Plus Bevacizumab in KRAS Wild Type Metastatic Colorectal Cancer.
OSU-12054Evan WuthrickA Phase I Trial of MEK Inhibitor GSK1120212 in Combination with Neoadjuvant 5-Fluorouracil Chemoradiation in the Treatment of KRAS, BRAF, and NRAS-Mutant Rectal Cancers
RTOG-1010Evan WuthrickA Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-overexpressing Esophageal Adenocarcinoma
OSU-12118Evan WuthrickPHASE I STUDY OF IPILIMUMAB COMBINED WITH WHOLE BRAIN RADIATION THERAPY OR RADIOSURGERY FOR MELANOMA PATIENTS WITH BRAIN METASTASES
OSU-08113Jun ZhangRetrospective Evaluation of the Prognostic Value of Total Tumor Volume Versus SUV in Patients with Lung Cancer Undergoing FDG PET/CT

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu